Allogene Therapeutics (ALLO) Research & Development (2019 - 2025)
Historic Research & Development for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $31.2 million.
- Allogene Therapeutics' Research & Development fell 3030.21% to $31.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $166.5 million, marking a year-over-year decrease of 1757.33%. This contributed to the annual value of $192.3 million for FY2024, which is 2083.66% down from last year.
- According to the latest figures from Q3 2025, Allogene Therapeutics' Research & Development is $31.2 million, which was down 3030.21% from $40.2 million recorded in Q2 2025.
- In the past 5 years, Allogene Therapeutics' Research & Development ranged from a high of $80.2 million in Q1 2023 and a low of $31.2 million during Q3 2025
- Moreover, its 5-year median value for Research & Development was $54.0 million (2021), whereas its average is $54.4 million.
- In the last 5 years, Allogene Therapeutics' Research & Development surged by 3970.88% in 2022 and then tumbled by 3487.0% in 2024.
- Quarter analysis of 5 years shows Allogene Therapeutics' Research & Development stood at $54.0 million in 2021, then skyrocketed by 39.71% to $75.4 million in 2022, then dropped by 27.52% to $54.7 million in 2023, then fell by 17.73% to $45.0 million in 2024, then tumbled by 30.7% to $31.2 million in 2025.
- Its Research & Development stands at $31.2 million for Q3 2025, versus $40.2 million for Q2 2025 and $50.2 million for Q1 2025.